✦ LIBER ✦

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

✍ Scribed by M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan Powell; Katherine M Bell-McGuinn; Clare Scott; Jeffrey N Weitzel; Ana Oaknin; Niklas Loman; Karen Lu; Rita K Schmutzler; Ursula Matulonis; Mark Wickens; Andrew Tutt

Book ID: 117306832
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 268 KB
Volume: 376
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(10)60893-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral poly(ADP-ribose) polymerase inhibit

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

✍ Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffr 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 594 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB

First in human trial of the poly(ADP)-ri

First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers

✍ R. Wenham; G. Wilding; R. Baird; L. Sun; C. Toniatti; M. Stroh; C. Carpenter; J. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 71 KB